Loading the session
Loading the session
Loading instrument
$12.45
−2.70%DelayedDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 20:37 IST · A quote does not mean the product is available to trade on your account.
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +18.2% (SPY −1.6%, XLV +13.5%). 3 months: −29.6% (SPY −0.4%, XLV +15.5%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: KLRA, SPY and XLV · as of 4 Nov 2026
8.3M shares were sold short at the 15 Oct 2026 settlement; covering them would take 5.7 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $12.80 was 1.6% below its 50-day average ($13.01).
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
4 Nov 2026 volume of 651.3K shares was 0.5× the average of the 30 sessions before it (1.3M), as the price rose 1.7%. SPY traded 1.5× its own average that session.
Daily volume against a 30-session baseline · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
October 20, 2026
+12.77%October 9, 2026
+16.10%June 22, 2026
+14.97%